Arvinas (ARVN) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Prothena (PRTA) has outperformed Arvinas (ARVN) over the past year, losing 16.8% versus a loss of 23.0%. Over five years, PRTA leads with a -86.4% price change compared with -91.2% for ARVN. Arvinas is the larger company by market cap ($495.5 million vs $471.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | PRTA |
|---|---|---|
| Share price | $7.68 | $9.18 |
| Market cap | $495.52M | $471.27M |
| 1-day change | +2.26% | +6.62% |
| YTD return | -36.68% | -9.84% |
| 1-year return | -22.97% | -16.81% |
| 5-year return | -91.18% | -86.43% |
| P/E ratio (TTM) | 29.54 | — |
| EPS (TTM) | $0.26 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $11.80 |
| 52-week low | $6.97 | $7.73 |
| Distance from 52-week high | -47.07% | -22.20% |
| Analyst consensus | buy | none |
| Avg. price target upside | +81.38% | +133.12% |
| Average volume | 788.21K | 484.51K |
| Shares outstanding | 64.52M | 51.34M |
| Employees | 246 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
ARVN vs PRTA FAQ
Which is bigger, Arvinas or Prothena?
Arvinas (ARVN) is larger, with a market capitalization of $495.52M compared with $471.27M for Prothena (PRTA).
Which stock has performed better over the past year, ARVN or PRTA?
PRTA returned -16.81% over the past 12 months, compared with -22.97% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Prothena in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.